Core Viewpoint - Tianyi Medical's subsidiary, Ningbo Tianyi Pharmaceutical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for blood dialysis concentrates, aimed at treating patients with acute and chronic renal failure [1] Product Registration - The registered product is intended for use in blood dialysis treatment for patients suffering from acute and chronic renal failure [1] - The actual sales performance of the registered product will depend on future market promotion efforts [1] Financial Impact - The company is currently unable to predict the impact of this product on future operating revenue [1]

Core Viewpoint - Tianyi Medical (301097.SZ) has received a Medical Device Registration Certificate from the National Medical Products Administration for its blood dialysis concentrate products, indicating a significant advancement in its product offerings in the blood purification sector [1]. Product Details - The blood dialysis concentrate consists of two components: A liquid (A液) and a dry powder (B粉). A liquid includes sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, and dialysis water, while B powder contains sodium bicarbonate [1]. - A liquid models are TR-YA3-01 and TR-YA3-02, with specifications of 5L and 10L per barrel, respectively. The B powder model is TR-FB-LBT1, with a specification of 650g per can [1]. Innovation and Market Impact - The innovative combination of A liquid and B powder offers the stability of liquid concentrates and the flexibility of dry powder formulations, allowing for more precise customization to meet clinical needs for dialysis products [1]. - The approval of this product expands the company's coverage in the blood purification field, showcasing its technological accumulation and rigorous quality management system [1]. - This development marks a deeper entry into the high-value core consumables of the medical device sector, enriching the overall solutions offered in blood purification and enhancing customer recognition and market synergy [1]. - The product's approval is expected to solidify and expand the company's leading position in the blood purification field, further improving its competitive advantage in the market [1].

Core Viewpoint - Tianyi Medical (301097.SZ) announced that its subsidiary, Ningbo Tianyi Pharmaceutical Technology Co., Ltd., has received a Medical Device Registration Certificate from the National Medical Products Administration for its product "Blood Dialysis Concentrate" [1] Group 1: Product Details - The blood dialysis concentrate consists of two components: A Concentrate (referred to as A Liquid) and B Powder (referred to as B Powder) [1] - A Liquid is composed of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, and dialysis water, while B Powder is made of sodium bicarbonate [1] - A Liquid models are TR-YA3-01 and TR-YA3-02, with specifications of 5L per barrel and 10L per barrel respectively; B Powder model is TR-FB-LBT1, with a specification of 650g per can [1]

Core Viewpoint - Tianyi Medical (301097.SZ) announced that its subsidiary, Ningbo Tianyi Pharmaceutical Technology Co., Ltd., has received a Medical Device Registration Certificate from the National Medical Products Administration for its product "Hemodialysis Concentrate" [1] Group 1 - The hemodialysis concentrate consists of two components: A Concentrate (referred to as A Liquid) and B Powder (referred to as B Powder) [1] - A Liquid is composed of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, and dialysis water, while B Powder is made of sodium bicarbonate [1] - A Liquid models are TR-YA3-01 and TR-YA3-02, with specifications of 5L and 10L barrels respectively; B Powder model is TR-FB-LBT1, with a specification of 650g can [1]

Investment Rating - The report maintains an "overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by more than 10% in the next six months [4][25]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index during the period from November 7 to November 20, 2025, with a decline of 1.51%, which is approximately 1.23 percentage points better than the CSI 300 index [11]. - Most sub-sectors within the industry recorded negative returns, with in vitro diagnostics and pharmaceutical distribution showing the highest gains of 2.37% and 2.27%, respectively, while medical R&D outsourcing and medical consumables experienced declines of 3.67% and 2.93% [12]. - Approximately 43% of stocks in the industry recorded positive returns during the same period, with the top performer, Hezhong China, seeing a weekly increase of 82.57% [16]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry as of November 20, 2025, was approximately 51.84 times, indicating a decrease in industry valuation [19]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a decline of 1.51% compared to the index's performance [11]. - Most sub-sectors recorded negative returns, with in vitro diagnostics and pharmaceutical distribution leading in gains [12]. - About 43% of stocks in the industry had positive returns, with significant variations in individual stock performance [16]. 2. Industry News - The report highlights the announcement from the Hebei Provincial Medical Products Procurement Center regarding the centralized procurement of 25 types of medical consumables, including biopsy needles and infusion ports [23]. 3. Company Announcements - Ningbo Tianyi Medical Devices Co., Ltd. received a medical device registration certificate for its blood dialysis concentrate products [24]. 4. Industry Outlook - The report suggests focusing on investment opportunities in the flu-related sector due to the onset of the flu season, recommending several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [25][27].

Core Viewpoint - Tianyi Medical's subsidiary, Ningbo Tianyi Pharmaceutical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its blood dialysis concentrate product [2] Group 1 - The product is officially recognized as a medical device, indicating compliance with regulatory standards [2] - This approval may enhance the company's market position in the medical device sector, particularly in dialysis treatment [2]

Group 1: Legal and Regulatory Issues - The National Healthcare Security Administration disclosed a bribery case involving Huang Mouyun, who was found guilty of bribing multiple healthcare professionals to increase sales of a traditional Chinese medicine product [1][2] - Huang Mouyun paid a total of 1.9263 million yuan in bribes to 15 doctors at a local hospital to secure sales, with the product achieving over 10 million yuan in sales since December 2018 [1][2] - The court ruled that Huang Mouyun's actions constituted bribery of non-state personnel, and he may receive a lighter sentence due to his confession [2] Group 2: Pharmaceutical Developments - Huason Pharmaceutical announced that its product, Amlodipine Besylate Tablets, has completed domestic production registration, aimed at enhancing market competitiveness amid an aging population [1] - Fosun Pharma's subsidiary has had its PD-1 monoclonal antibody, used for gastric cancer treatment, included in the breakthrough therapy designation, marking a significant advancement in cancer treatment options [3] - Tianyi Medical received a medical device registration certificate for its blood dialysis concentrate, which is intended for patients with acute and chronic renal failure [4] Group 3: Clinical Research and Results - Innovent Biologics reported that its drug, Ma Shidu Peptide, achieved a weight reduction of up to 20.1% in obese patients during a Phase III clinical trial, with significant improvements in various health metrics compared to the placebo group [5][6] - The trial involved 462 participants, with the Ma Shidu Peptide group showing an average weight loss of 18.55% after 60 weeks, while the placebo group only lost 3.02% [6] Group 4: Corporate Governance - Changchun High-tech announced a change in the shareholding structure of its controlling shareholder, which will not affect the company's operations or control [4][5] - Guangji Pharmaceutical's independent director, Guo Wei, resigned due to personal reasons, which may impact the board's composition and the presence of accounting professionals [8]

Core Viewpoint - Tianyi Medical (301097.SZ) has received a Medical Device Registration Certificate from the National Medical Products Administration for its subsidiary Ningbo Tianyi Pharmaceutical Technology Co., Ltd, enhancing its product portfolio and competitive edge in the market [1]. Group 1: Product Registration Details - The registered product is a blood dialysis concentrate, classified as a Class III medical device, with a registration number of Guo Xie Zhu Zheng 2025310230, valid from November 13, 2025, to November 12, 2030 [2]. - The blood dialysis concentrate consists of two components: A concentrate (A liquid) and a connected dry powder (B powder), designed to meet the personalized treatment needs of patients with acute and chronic renal failure [2]. - A liquid is composed of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, and dialysis water, while B powder contains sodium bicarbonate, utilizing acetic acid as a buffer in a medium calcium formulation [2]. Group 2: Strategic Implications - The acquisition of the medical device registration certificate extends the company's product chain and enriches its product categories, which is beneficial for enhancing the company's overall competitiveness in the healthcare market [2].

Core Viewpoint - Tianyi Medical (301097) announced that its subsidiary, Ningbo Tianyi Pharmaceutical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its blood dialysis concentrate, which is intended for the treatment of acute and chronic renal failure patients undergoing hemodialysis [1] Company Summary - Tianyi Medical's subsidiary has successfully obtained regulatory approval for a new medical product, indicating progress in its product development and potential market entry [1] - The blood dialysis concentrate is specifically designed for patients with renal failure, highlighting the company's focus on addressing critical healthcare needs [1] Industry Summary - The approval of the blood dialysis concentrate aligns with the growing demand for renal care solutions, particularly in the context of increasing incidences of kidney-related diseases [1] - This development may enhance competition within the medical device sector, particularly in the field of dialysis treatment [1]

Core Viewpoint - Tianyi Medical (301097.SZ) has received a medical device registration certificate from the National Medical Products Administration for its blood dialysis concentrate, which includes A concentrate and B powder, enhancing its product offerings and competitive edge in the market [1] Group 1 - Tianyi Pharmaceutical, a subsidiary of Tianyi Medical, has obtained a medical device registration certificate for its blood dialysis concentrate [1] - The blood dialysis concentrate consists of A liquid, which includes sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, and dialysis water, and B powder, which contains sodium bicarbonate [1] - The combination of A liquid and B powder offers advantages of both types of concentrates, catering to personalized clinical treatment needs [1] Group 2 - The acquisition of the registration certificate extends the company's product chain and enriches its product categories [1] - This development is expected to enhance the overall competitiveness of the company in the medical device industry [1]